Details
Stereochemistry | RACEMIC |
Molecular Formula | C12H18Cl2N2O |
Molecular Weight | 277.19 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(Cl)=C1
InChI
InChIKey=STJMRWALKKWQGH-UHFFFAOYSA-N
InChI=1S/C12H18Cl2N2O/c1-12(2,3)16-6-10(17)7-4-8(13)11(15)9(14)5-7/h4-5,10,16-17H,6,15H2,1-3H3
DescriptionCurator's Comment: description was created based on several sources, including
https://www.deadiversion.usdoj.gov/drug_chem_info/clenbuterol.pdf
Curator's Comment: description was created based on several sources, including
https://www.deadiversion.usdoj.gov/drug_chem_info/clenbuterol.pdf
Clenbuterol is agonist of beta2 adrenergic receptor. In some countries it is used as bronchodilator for treatment of asthma, but is not approved in USA. The drug is abused by bodybuilders and athletes for its ability to increase lean muscle mass and to reduce body fat. In 1998 FDA approved the clenbuterol-based Ventipulmin Syrup as a prescription-only drug for treatment of airway obstruction in horses.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL210 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19245211 |
570.0 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Sources: https://www.rlsnet.ru/tn_index_id_1750.htm |
Primary | SPIROPENT Approved UseTreatment of asthma, chroncic obstructive bronchitis, emphysema and other diseases. |
||
Primary | CLENBUTEROL Approved UseTreatment of asthma, chroncic obstructive bronchitis, emphysema and other diseases. |
PubMed
Title | Date | PubMed |
---|---|---|
[Novel quantitative assessment of the tremorogenic effects of the beta 2-mimetics clenbuterol and salbutamol after oral administration]. | 1985 |
|
Clenbuterol-induced tardive dyskinesia. | 1991 Oct |
|
Clenbuterol and anabolic steroids: a previously unreported cause of myocardial infarction with normal coronary arteriograms. | 1998 Aug |
|
[A case of immotile-dyskinetic cilia syndrome responding to clenbuterol hydrochloride and azithromycin]. | 2002 Jul |
|
Beta-adrenergic stimulation induces interleukin-18 expression via beta2-AR, PI3K, Akt, IKK, and NF-kappaB. | 2004 Jun 25 |
|
Endotoxin-induced liver damage in rats is minimized by beta 2-adrenoceptor stimulation. | 2004 Mar |
|
Dobutamine inhibits phorbol-myristate-acetate-induced activation of nuclear factor-kappaB in human T lymphocytes in vitro. | 2004 Nov |
|
Beta-adrenergic receptor modulation of the LPS-mediated depression in CYP1A activity in astrocytes. | 2005 Mar 1 |
|
[Enantiomeric resolution of clenbuterol hydrochloride using (2R, 3R)-Dicyclohexyl tartrate impregnated thin layer chromatography]. | 2005 Nov |
|
Beta(2)-adrenoceptor agonist clenbuterol reduces infarct size and myocardial apoptosis after myocardial ischaemia/reperfusion in anaesthetized rats. | 2010 Jul |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.rlsnet.ru/tn_index_id_1750.htm
For treatmen of airways obstruction the clenbuterol is administered orally, 15ml of syrop 2-3 times a day.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2993621
Affinity towards beta2 adrenergic receptors was measured using the recombinant receptor expressed in Sf-9 cells. Cell membrane homogenates were incubated with 0.15 nM of radioligand [3H]CGP1217 in the absence of presence of the clenbuterol. Following incubation, the samples were filtered rapidly under vacuum through through glass fiber filters, the filters were dried, and counted for radioactivity in a scintillation counter. Clenbuterol was binding to beta2 receptor with Ki of 0.58 uM.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QR03CC13
Created by
admin on Fri Dec 15 15:40:55 GMT 2023 , Edited by admin on Fri Dec 15 15:40:55 GMT 2023
|
||
|
WHO-VATC |
QR03AC14
Created by
admin on Fri Dec 15 15:40:55 GMT 2023 , Edited by admin on Fri Dec 15 15:40:55 GMT 2023
|
||
|
WHO-VATC |
QR03CC90
Created by
admin on Fri Dec 15 15:40:55 GMT 2023 , Edited by admin on Fri Dec 15 15:40:55 GMT 2023
|
||
|
WHO-ATC |
R03CC13
Created by
admin on Fri Dec 15 15:40:55 GMT 2023 , Edited by admin on Fri Dec 15 15:40:55 GMT 2023
|
||
|
CFR |
21 CFR 530.41
Created by
admin on Fri Dec 15 15:40:55 GMT 2023 , Edited by admin on Fri Dec 15 15:40:55 GMT 2023
|
||
|
CFR |
21 CFR 520.452
Created by
admin on Fri Dec 15 15:40:55 GMT 2023 , Edited by admin on Fri Dec 15 15:40:55 GMT 2023
|
||
|
FDA ORPHAN DRUG |
451614
Created by
admin on Fri Dec 15 15:40:55 GMT 2023 , Edited by admin on Fri Dec 15 15:40:55 GMT 2023
|
||
|
NCI_THESAURUS |
C319
Created by
admin on Fri Dec 15 15:40:55 GMT 2023 , Edited by admin on Fri Dec 15 15:40:55 GMT 2023
|
||
|
FDA ORPHAN DRUG |
546316
Created by
admin on Fri Dec 15 15:40:55 GMT 2023 , Edited by admin on Fri Dec 15 15:40:55 GMT 2023
|
||
|
WHO-ATC |
R03CC63
Created by
admin on Fri Dec 15 15:40:55 GMT 2023 , Edited by admin on Fri Dec 15 15:40:55 GMT 2023
|
||
|
WHO-ATC |
R03AC14
Created by
admin on Fri Dec 15 15:40:55 GMT 2023 , Edited by admin on Fri Dec 15 15:40:55 GMT 2023
|
||
|
FDA ORPHAN DRUG |
653918
Created by
admin on Fri Dec 15 15:40:55 GMT 2023 , Edited by admin on Fri Dec 15 15:40:55 GMT 2023
|
||
|
WHO-VATC |
QG02CA91
Created by
admin on Fri Dec 15 15:40:55 GMT 2023 , Edited by admin on Fri Dec 15 15:40:55 GMT 2023
|
||
|
NCI_THESAURUS |
C48149
Created by
admin on Fri Dec 15 15:40:55 GMT 2023 , Edited by admin on Fri Dec 15 15:40:55 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
673
Created by
admin on Fri Dec 15 15:40:55 GMT 2023 , Edited by admin on Fri Dec 15 15:40:55 GMT 2023
|
PRIMARY | |||
|
SUB06651MIG
Created by
admin on Fri Dec 15 15:40:55 GMT 2023 , Edited by admin on Fri Dec 15 15:40:55 GMT 2023
|
PRIMARY | |||
|
XTZ6AXU7KN
Created by
admin on Fri Dec 15 15:40:55 GMT 2023 , Edited by admin on Fri Dec 15 15:40:55 GMT 2023
|
PRIMARY | |||
|
37148-27-9
Created by
admin on Fri Dec 15 15:40:55 GMT 2023 , Edited by admin on Fri Dec 15 15:40:55 GMT 2023
|
PRIMARY | |||
|
100000080213
Created by
admin on Fri Dec 15 15:40:55 GMT 2023 , Edited by admin on Fri Dec 15 15:40:55 GMT 2023
|
PRIMARY | |||
|
D002976
Created by
admin on Fri Dec 15 15:40:55 GMT 2023 , Edited by admin on Fri Dec 15 15:40:55 GMT 2023
|
PRIMARY | |||
|
XTZ6AXU7KN
Created by
admin on Fri Dec 15 15:40:55 GMT 2023 , Edited by admin on Fri Dec 15 15:40:55 GMT 2023
|
PRIMARY | |||
|
DTXSID7022833
Created by
admin on Fri Dec 15 15:40:55 GMT 2023 , Edited by admin on Fri Dec 15 15:40:55 GMT 2023
|
PRIMARY | |||
|
2783
Created by
admin on Fri Dec 15 15:40:55 GMT 2023 , Edited by admin on Fri Dec 15 15:40:55 GMT 2023
|
PRIMARY | |||
|
3264
Created by
admin on Fri Dec 15 15:40:55 GMT 2023 , Edited by admin on Fri Dec 15 15:40:55 GMT 2023
|
PRIMARY | |||
|
CLENBUTEROL
Created by
admin on Fri Dec 15 15:40:55 GMT 2023 , Edited by admin on Fri Dec 15 15:40:55 GMT 2023
|
PRIMARY | |||
|
DB01407
Created by
admin on Fri Dec 15 15:40:55 GMT 2023 , Edited by admin on Fri Dec 15 15:40:55 GMT 2023
|
PRIMARY | |||
|
174690
Created by
admin on Fri Dec 15 15:40:55 GMT 2023 , Edited by admin on Fri Dec 15 15:40:55 GMT 2023
|
PRIMARY | |||
|
2580
Created by
admin on Fri Dec 15 15:40:55 GMT 2023 , Edited by admin on Fri Dec 15 15:40:55 GMT 2023
|
PRIMARY | RxNorm | ||
|
m3615
Created by
admin on Fri Dec 15 15:40:55 GMT 2023 , Edited by admin on Fri Dec 15 15:40:55 GMT 2023
|
PRIMARY | Merck Index | ||
|
253-366-0
Created by
admin on Fri Dec 15 15:40:55 GMT 2023 , Edited by admin on Fri Dec 15 15:40:55 GMT 2023
|
PRIMARY | |||
|
758633
Created by
admin on Fri Dec 15 15:40:55 GMT 2023 , Edited by admin on Fri Dec 15 15:40:55 GMT 2023
|
PRIMARY | |||
|
CHEMBL49080
Created by
admin on Fri Dec 15 15:40:55 GMT 2023 , Edited by admin on Fri Dec 15 15:40:55 GMT 2023
|
PRIMARY | |||
|
C65335
Created by
admin on Fri Dec 15 15:40:55 GMT 2023 , Edited by admin on Fri Dec 15 15:40:55 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
METABOLITE (PARENT)
SALT/SOLVATE (PARENT)